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SUMMARY
In the current minireview, we focus on
genetic mouse models of Alzheimer’s disease
(AD). Because various excellent, up-to-date
reviews, special issues, and reliable websites are
already dedicated to the genetics of Alzheimer’s
disease in general and of animal models in
particular, this review is not meant to be
comprehensive. Rather, we aim to steer the
Alzheimer’s novice through the recent mouse
literature on AD. Special attention will be paid
to genetic models that have been tested
behaviorally.
INTRODUCTION
Alzheimer’s disease (AD) is the most common
cause of dementia in the elderly, the fourth most
common cause of death in westem industrialized
nations, and one of the major contributors to the
global burden of disease (WHO, 2000). No
disease-modifying treatment is currently available.
The onset of dementia in AD is insidious, and its
course is relentlessly progressive and characterized
by global cognitive decline, involving memory,
orientation, judgment, and reasoning. Nearly 4.5
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million individuals are currently afflicted in the
United States (U.S.), an incidence expected to rise
to up to 16 million by the year 2050 (Hebert et al.,
2003).
Extracellular neuritic plaques and intraneuronal
neurofibrillary tangles (NFTs) are the two classical
hallmark microscopic pathologies of AD
(Lovestone & McLoughlin, 2002; Selkoe, 2004).
Neuritic plaques comprise a dense amyloid core of
[3-amyloid peptide (AI3) that is surrounded by
dystrophic neurites. These plaques precipitate and
deposit around neurons, mainly those in the limbic
system and cortex (Glenner & Wong, 1984a, 1984b;
Glenner et al., 1984). This ’choking’ mechanism
will ultimately lead to neuronal death, which is
believed to be responsible for phenotypical
dementia in affected patients (Wilquet & De
Strooper, 2004).
The microtubule-associated protein, tau, is the
principal component of NFTs (Stoothoff &
Johnson, 2005). Tau function is regulated by phos-
phorylation and in AD, tau is abnormally hyper-
phosphorylated, leading to disruption of micro-
tubule dynamics, impaired axonal transport, and
tau polymerization, which results in the formation
of intraneuronal NFTs and ultimately neuronal
death. For a pathological diagnosis of AD, both
neuritic plaques and NFTs are required.
It is now generally believed that abnormal
production and aggregation of AI3 (especially the
more fibrillogenic A42 isoform) are primary
pathogenic events in AD and that NFTs are farther
downstream in the pathogenesis, commonly referred
(C) 2005 Freund & Pettman, U.K. 299300 Y.S. MINEUR ET AL.
TNomy
Euronmen
’
P mismeabotlsm
1
fac,o.s
M.produou aud. aregafiou, ofA4. Tan
ffuse plaques
PHF-tau
t- Nearoualdfuaca
anddea
D\E NTIA
Fig. 1: Schematic overview ofthe amyloid cascade hypothesis See text for more information.
to as the "amyloid hypothesis" (Fig. 1). This
hypothesis is to some extent controversial as
plaques and tangles have been found in the brains
ofnon-demented individuals as well (albeit in lower
abundance). Moreover, the exact sequence and
implication of the different biological processes
involved in AD are not yet entirely clear. Although
neurodegeneration, amyloid plaques, and NFTs are
widely accepted as part of the disease, to
determine to what extent those factors contribute
to dementia and to what extent they are inter-
connected to each other remains difficult.
Nevertheless, recent studies have revealed that
soluble oligomers of AI3 can disrupt synaptic
function (Walsh & Selkoe, 2004), mediate neuronal
dysfunction in AD (Walsh & Selkoe, 2004), and
are both necessary and sufficient to disrupt learning
behavior in a manner that is both rapid, potent and
transient (Cleary et al., 2005). For a detailed
discussion on the amyloid hypothesis, the reader is
referred to Hardy & Selkoe (2002) and Marchesi
(005).
GENETICS
As in most complex disorders, genes play an
important role in the pathogenesis of AD. One of
the most effective methods to ascertain the input
of genetic factors is the classical twin method. By
comparing genetically related individuals, e.g.
monozygotic and dizygotic twins, this method is
able to estimate the relative contribution of both
genetic and environmental factors, as well as theirGENETIC MOUSE MODELS OF ALZHEIMER’S DISEASE 301
interaction for more detailed information, see,
among others Boomsma et al., 2002). Studies over
the last decades have rendered estimates of the
heritability of AD, i.e. the proportion of phenol-
typic variation that can be attributed to genetic
effectsmbetween 48 and 75% (Bergem et al., 1997;
Raiha et al., 1996), depending on, among others,
the age of the population under investigation
(early-onset vs. late-onset) and the type of study
(incidence vs. prevalence).
The search for the actual genes has proven to
be difficult. To date, possession of the 134 allele of
ApoE is the most robust genetic susceptibility
factor for late-onset AD but is neither necessary
nor sufficient to cause disease (Tanzi & Bertram,
2005). Other genes involved are the genes
encoding amyloid precursor protein (APP), pre-
senilin-1 (PSEN1), and presenilin-2 (PSEN2).
Specific mutations in these genes cause early-onset
familial AD (EOFAD). First discovered in 1991
(Goate et al., 1991), the number of these fully
penetrant mutations has expanded exponentially.
Although such mutations are rare (< 5% of all
AD cases), the affected geneswand the biochemical
pathways they represent--are excellent starting
points for the genetic and functional analysis of
AD. Mutations in the gene encoding tau, however,
cause a range of different disorders, which are
collectively referred to as "tauopathies" (Ingram &
Spillantini, 2002). None of these disorders has any
appreciable AD pathology, confirming the contri-
bution of tau to be further downstream in the
pathogenesis ofAD.
Another advantage, from a genetic point of
view, in the study ofAD is the central role of
in the amyloid hypothesis. Hence, by definition
(but in contrast to most psychiatric disorders), a
clearly defined neuronal intermediate phenotype,
also called an endophenotype, can be further
explored. This approach is extremely useful in the
genetic analysis of a complex disorder because
for more information http://www.molgen.ua.ac.be/ADMutations
identifying the effect of a gene on a more
elementary (neuro)biological trait is easier than
identifying its effect on a complex trait with
dichotomous diagnostic categories.
A[3 is a 40-42 amino acid peptide derived from
proteolytic processing of a much larger precursor
molecule, the amyloid precursor protein (APP).
The proteases catalyzing this reaction are termed
"secretases": 13-secretase (BACE1) first cleaves at
the N-terminus of AI3 and then 13-secretase cleaves
at the C-terminus (Fig. 2). The bulk of APP,
however, is cleaved by t-secretase within the AI3
domain to produce the C-terminal fragment, C83,
which can be further cleaved intramembranously
by /-secretase to produce peptide P3 and the APP
intracellular domain (AICD), which can trans-
locate to the nucleus to participate in gene trans-
cription events (Cao & Sudhof, 2001; see Fig. 2).
Mismetabolism of APP, especially an increase
of the more fibrillogenic cerebral A[3. ending at
position 42 (AI342) compared with the one ending
at position 40 (AI340), can lead to an abnormal
production and aggregation of All and as a result
to AD. In consequence, the genes encoding the -,
13-, and ),-secretases can be considered candidate
genes for AD. Other candidate genes are those that
code for proteins affecting AI3 clearance and de-
gradation, as well as AI3 toxicity and inflamma-
tion. For a review on the genetics of the amyloid
cascade, the reader is referred to Tanzi & Bertram
(2005).
ANIMAL MODELS
Many AD studies have been aimed at the
analysis and manipulation of AI3 peptides. In this
respect, animal models have been very valuable as
nearly all studies in humans are necessarily based
on postmortem tissues where there is considerable
variation in quality because of the technical
(agonal state of the brain, post-mortem interval,
tissue fixation and storage, tissue pH) and302 Y.S. MINEUR ET AL.
biological (age at death, gender, medication and
substance abuse) state of the autopsy brain (for
detailed information, see Katsel et al., 2005).
There are other reasons, though, why animal
models are indispensable. Their environment can
be controlled and hence manipulated. Sample sizes
can be increased when necessary. Perhaps most
important, animals can be experimented upon and,
accordingly, can provide answers to questions that
cannot be answered in humans.
CD
P3
Fig. 2: APP processing pathways. A: APP is an integral transmembrane protein (N-terminal is extracellular; C-terminal
is cytoplasmatic). The C-terminal of AI3 (red ’block’) is embedded within the cell membrane (area between
dashed lines). B: Non-amyloidogenic pathway. APP is cleaved by the membrane-associated metalloprotease a-
secretase within the AI3 domain, thereby preventing the formation of AI3. This results in the release ofthe large
soluble extracellular N-terminal portion ofAPP (APPsa) and C83 (C-terminal fragment of 83 residues). C83
might be further processed by ),-secretase to release the p3 peptide, which is considered non-amyloidogenic,
and the APP intracellular domain (AICD). C: Amyloidogenic pathway. APP is cleaved by two distinct
proteases: 13- and ),-secretase. First, 13-Secretase, (BACE1 13-site APP-cleaving enzyme) cleaves APP at the N-
terminal region ofthe AI3 sequence, resulting in the soluble APPsl3 and the amyloidogenic C99 (C-terminal
fragment of 99 residues). Second, y-secretase cleaves C99, resulting in AICD and AI3.GENETIC MOUSE MODELS OF ALZHEIMER’S DISEASE 303
Although this review will concentrate on
mouse models of AD, invertebrate models such as
Drosophila sp. and C. elegans should not be dis-
carded too easily. Despite their clear disadvantages
--they are not mammals and therefore lack the
brain structures typical of those--they do have
added value in the study of AD, especially, at a
practical level. They are smaller, cheaper to house
and breed, and have shorter generation times than
any mammal, which allows the breeding of many
generations in a short time span. Last, but certainly
not least, is the advantage of a less stringent
legislation. Thus, transgenic fly and worm AD
models exist both with regard to AI3 and tau
expression (for recent reviews, see Brandt et al.,
2005; Lee et al., 2005; Link, 2005).
Mice are the most popular animal models for
AD nowadays, the main reason being that their
genome can be manipulated relatively easily. This
advantage has resulted in a variety of genetic
mouse models, although rat models do exist as
well (see for instance, Hu et al., 2004). Before we
dive into the pool of knockouts, knockins, .and
transgenics, we would like to remind the reader of
what a good animal model for AD theoretically
stiould be like.
1. First, this model should be reliable, which
refers to the stability and reproducibility of the
phenotype, across time and preferably also
across laboratories, although the latter is far
from easy (Crabbe et al., 1999).
2. Second, this model should have validity with
AD. Validity implies four different features.
Face validity refers to the similarity between
the animal model and the disease of interest,
i.e. AD. Hence, the model should mimic the
behavioral characteristics ofAD---e.g. cognitive
decline--as well as possible.
3. Construct validity is another factor and exists
when the model either relies or elucidates the
same basic underlying mechanism as AD, such
as the accumulation of AI3 peptides and/or
hyperphosphylation of tau. Genetic validity
exists when the risk for a disease is known to
involve similar genetic components both in
humans and in the animal model, whereas
predictive validity usually refers to how useful
animal models are for predicting the efficacy
and safety of drugs.
MOUSE MODELS FOR ALZHEIMER’S DISEASE
At the start of this outline, it is important to
realize that both in (semi-) natural and in
laboratory conditions mice do not develop plaques
and tangles, hence the development of mouse
models for AD implies manipulations by the
experimenter. Such manipulations can be either
genetic or invasive, the latter generally being the
exogenous administration of different AI3 peptides
into the normal rodent brain. Both techniques have
their advantages and handicaps but are essentially
complementary. In this review, we will focus on
genetically modified mouse models of AD. For a
recent review on mouse models of AD involving
exogenous AI3 administration and their comparison
to transgenic models, the reader is referred to
Stephan & Phillips (2005).
Genetically modified strains
The amyloid hypothesis has also played a
major role in the development of transgenic mouse
models. By definition, genes that code for APP
and the enzymes involved in the processing of
APP to AI3 are good candidates for manipulation;
therefore, not surprisingly, to date, a multitude of
genetically modified strains exist that attempt to
unravel specific parts of the amyloid pathway. The
genetically modified strains entail the following:
(a) Classical and conditional knockouts (KO). In
classical KOs, the function of the gene under
investigation is abolished from a very early
stage of development. In conditional KOs,
there is either a temporal restriction (gene304 Y.S. MINEUR ET AL.
function is abolished at certain premeditated
time windows) or a regional restriction (no
gene function in certain brain regions). A
combination ofboth is also possible;
(b) Transgenics, in which a foreign gene, e.g.
human APP, is inserted into the genome;
(c) K nockins, in which very specific mutations are
introduced in the gene leading to a loss of
activity of the proteins encoded by the targeted
gene (although the gene expression per se is
not voided as it is in KOs).
Moreover, combinations of (a), (b), and (c) are
possible. Strains having one gene knocked out and
another inserted into the genome and overex-
pressed (KO/Tg) are quite common nowadays.
Even triple transgenics are being used in mouse
models ofAD.
APP transgenics
The first successful genetically modified
mouse models in AD research were transgenic and
increased the load of A[3 by increasing the load of
its precursor APP. In general, a human APP
(hAPP) genemusually a mutant form linked to
inherited early onset forms ofAD--is inserted into
the genome. If successful, this procedure leads to
the overexpression of the transgene in question
and, consequently, to increased levels of APP. To
our knowledge, five distinct hAPP transgenics
have been developed: PDAPP, Tg2576, APP23,
TgCRND8, and J20. Each transgenic has its own
genetic characteristics (different mutations, different
promoters, different background), which leads to
different expression levels and both qualitatively
and quantitatively different levels of neuroana-
tomical abnormalities. All have been tested
behaviorally; some extensively, others not. A close
look at those lines that have been tested in great
detail, such as PDAPP and Tg2576, demonstrates
that (genetically induced) high APP levels lead to
high AI3 levels, which, in turn, lead to robust
cognitive disturbances. Thus, both lines can show
learning deficits over time and in different
laboratories. This point is rather important as the
replicability of the (endo)phenotype over time and
across laboratories are essential conditions for a
reliable animal model. An additional strength of
these particular lines is that they show deficits in
several different cognitive tets, which indicates
that the behavioral consequences of high AI3
levels, i.e. poorer performance in cognitive tests
compared with control animals, are general rather
than test specific. For instance, Tg2576 mice,
developed by Hsiao et al. (1996), have compara-
tively more difficulties in a specific version of the
water navigation task than their control littermates.
Both their acquisition of hidden platform locations
and their retention of spatial reference information
are affected. This effect is progressive and starts as
early as 6 months of age (Westerman et al., 2002).
In a different laboratory, the same transgenics also
show performance deficits in an adapted version of
the Barnes maze (Pompl et al., 1999), whereas in
yet another lab they perform poorer in a T-maze
alternation task and are impaired at acquiring fear
to the conditioning context (Corcoran et al., 2002).
Not unexpectedly, the search for biochemical
targets has widened beyond overexpression of
mutant forms of the human APP gene. From a
genetic point of view, all the genes encoding the
secretases that cleave the APP molecule can be
considered compelling candidate genes for AD.
Especially interesting are the 13- and 3t-secretases,
which catalyze the processing ofAPP to the various
AI3 peptides, and a-secretase, which is part of the
non-amyloidogenic pathway.
secretase
BACE1 is the most important 13-secretase in
neurons. Both transgenic and knockout BACE1
mice have been developed and, interestingly, theirGENETIC MOUSE MODELS OF ALZHEIMER’S DISEASE 305
phenotypic changes are opposite: The KOs are
more anxious than controls and transgenics are
bolder. This observation suggests the involvement
of BACE in anxiety and not so much in cognition
as might have been expected. The next step in
elucidating the role of 13-secretase in AD was the
development of double transgenics, in this case the
crossbreeding of mice overexpressing hAPP with
those either lacking or overexpressirlg BACE1
(BACE/Tg2576 and hBACE/Tg2576, respectively).
As expected, double transgenics (hBACE/Tg2576)
have accelerated amyloid pathology, high levels of
both total A[3 and AI342, and greater numbers of
plaques than hAPP mice alone. The removal of
BACE1 in the presence ofhAPP, however, rescues
certain of the cognitive deficits associated with
(for references, see Kobayashi & Chen, 2005).
T-secretase
The secondary cleavage in the processing from
APP to AB42 requires the activity of the y-
secretase enzyme. In fact, functional /-secretase is
a complex holoenzyme consisting of several indi-
vidual enzymes, including PSI, PS2, Nicastrin,
Aph-1, and Pen-2 (De Strooper& Woodgett, 2003;
Francis et al., 2002). Especially the presenilins
(PS1, PS2) have been the target of intense
investigation. KOs, transgenics, and KIs have been
used, as well as double and even triple transgenics.
Although PS KO mice are not viable (Shen et al.,
1997), this problem was circumvented by the
development of conditional KOs (cKO), in which
the loss of the gene was limited to the postnatal
forebrain. PSlcKO animals showed modest cogni-
tive impairments in long-term spatial reference
memory and retention (Yu et al., 2001).
Mice overexpressing PS1 (hPS1), however,
show only minor behavioral disturbances. Interest-
ingly, KIs with a directed missense mutation in the
endogenous murine PSI overproduce AI342, but
develop no plaques. These mice show poorer
performance in the object recognition test, but not
in the water-navigation task, suggesting changes of
PSI to affect non-hippocampal memory systems
(Huang et al., 2003; Janus et al., 2000). PS2 KOs
are both viable and fertile and do not appear to
show any neurobehavioral abnormalities, whereas
PS2 transgenics and KIs perform more poorly in
the water-navigation task.
Following an experimental concept similar to
that of the hAPP x BACE1, both double trans-
genics and cPS//APP have been developed. Com-
pared with controls, double transgenics accumulate
AI3 quicker and at higher levels and, consequently,
perform poorer in a multitude of cognitive tests
(see Kobayashi &Chen, 2005). Mechanistically in
line with the hAPP x PS findings is the
observation that cPS//APP mice, which carry a
conditional postnatal neuron-specific cre/lox KO
version of the PSI gene, develop no amyloid
plaques and behave normally in an object
recognition task (Dewachter et al., 2002),
suggesting /-secretase inhibition is a promising
target for putative treatment strategies.
-secretase
The third secretase involved in APP processing
is the {x-secretase, which metabolizes about 90% of
APP. To a certain extent, the {x-secretase can be
considered the ’good’ secretase as it produces
peptides not--or far less than the AI3s-associated
with amyloid toxicity (see Fig. 2). Thus, although
the P3 fragment is also a component of certain
amyloid plaques in AD, there have been very few
reports of P3 having apoptotic or any other kind of
deleterious activity in neurons. As a result, the
secretase-processing pathway has been described
as the non-amyloidogenic pathway (Naslund et al.,
1994; Wei et al., 2002). A number of enzymes can
act as t-secretase in the brain, including the ADAM
proteins (ADAM9, ADAM10, and ADAM17).
ADAM stands for A Disintegrin and Metallo-306 Y.S. MINEUR ET AL.
proteinase; its members have apparently redundant
a-secretase cleavage activities but differential ex-
pression patterns (Buxbaum et al., 1998; Kark-
kainen et al., 2000; Lammich et al., 1999).
ADAM 10 and ADAM 17 single knockouts
have been shown to be lethal embryonically,
whereas ADAM9 knockouts are viable and show
no apparent abnormalities. While overexpression
of a-secretase, i.e. ADAM 10, itself is not harmful,
it restores basic neural function in a transgenic
model of AD. Thus in an extensive study Postina
et al. (2004) showed that enhanced a-secretase
expression prevents the development of plaques in
old animals overexpressing hAPP. In contrast,
overexpression of a largely inactive ADAM10 on
an APP background exacerbates amyloid deposi-
tion. The authors also tested these animals in the
water navigation task and observed deficits in the
acquisition phase of place learning and in the
probe trial, whereas the double transgenicsmboth
overexpressing ADAM 10 and hAPP--performed
as well as control animals. Long term potentiation
(LTP) was also improved in the double transgenics
as opposed to single APP transgenics, suggesting a
fundamental rescue of synaptic function via the
increased activity of t-secretase. Their results on
,the neuroprotective role of a-secretase are in line
with previous findings from Moechars et al. (1996)
on a double transgenic overexpressing hAPP with
a disturbed a-secretase cleavage site. The resulting
APP/RK mice had increased APP expression in
their brains with a shift toward 13-site cleavage
amyloid peptides and had shorter life spans than
control animals (Moechars et al., 1999). APP/RK
mice also showed neuroanatomical abnormalities in
the amygdala, cortex, and hippocampus and were
observed to be more aggressive and hyperactive.
Tall
overexpress human wild-type tau and/or mutated
forms of human tau known to be associated with
frontotemporal dementia and parkinsonism
(abbreviated FDTP. In humans, tau proteins are
encoded by a single gene on chromosome 17.
Alternative splicing of the mRNA generates six
different brains isoforms, which can be divided in
two classes: proteins that contain three C-terminal
imperfect repeat domains (3R) and proteins that
contain 4 repeats (4R). Most transgenic models
overexpress the mutated 4R tau form in one way or
another, varying from ’normal’ 4R tau to one
mutated form (P301L, P301S, V337M) to multiple
mutations. Although numerous tau pathologies
have been found in the brains of these transgenics
(for reviews see Brandt et al., 2005; Lee et al.,
2000), few studies have exposed these mice to
extensive behavioral testing.
Interestingly, Tanemura et al. (2002) found 11-
mo-old transgenics overexpressing the V337
mutant gene to be less anxious than control litter-
mates on the elevated-plus maze, whereas no
difference was observed in the water-navigation
task. This result suggests the presence of a very
specific (non-spatial) cognitive deficit in which Tg
mice may not be able to discriminate fearful con-
ditions from fearless ones. Supporting this inter-
pretation, the transgenics showed little habituation
to the elevated plus maze and open field, whereas
control animals showed clear habituation patterns.
Further studies on neurodegeneration in the hippo.
campus of these transgenicsmirregular shaping o
30% to 70% of the neurons, as well as diminishe
neural responses recorded from hippocampa
slicesmmight shed some light on the differentia
functional (spatial vs. non-spatial) implications.
The same laboratory also tested the behavic
of mice overexpressing another mutated 4R ta
gene, R406W, which in humans causes a tau
pathy that clinically resembles AD. Within 48
In addition to these ’AI3 transgenics’, various
transgenic mouse models have been developed that see again http://www.molgen.ua.ac.be/AD Mutations for mc
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after conditioning, the transgenics showed reduced
levels of fear response during the cued but not the
contextual testing in comparison with control
littermates at an age of 16-23 months. Fifteen days
after conditioning, the animals also showed lower
levels of fear response during the contextual testing,
suggesting that memory loss may be more. pro-
nounced in longer retention delays in aged trans-
genics. Taken together, the results of that study
suggest the presence of associative memory im-
pairments in mice overexpressing the mutated tau
gene. This effect seems to be rather specific as
transgenics either did not differ or differed only
slightly from controls with regard to other behav-
ioral and sensorimotor tests. Neuroanatomically,
transgenics are characterized by congophilic tau
inclusions, predominantly in the hippocampus,
amygdala, and neocortex, areas that are well
established to be involved in memory formation
(Tatebayashi et al., 2002).
Triple Transgenics
To study the interaction between A[3 and tau,
Oddo et al. (2003) went one step further and
developed a triple-transgenic using a novel strategy
in which two transgenes, Tg2576 and tauP301L,
were microinjected into single-cell embryos
obtained from homozygous PSl-knockin mice.
Triple-transgenic (3xTg) mice develop age-related
and progressive neuropathologies, including plagues
and tangles. The pattern of progression--A[3 first
in cortical regions, then later in hippocampus and
amygdala; tau the other way around--closely
mimics that observed in AD. One of the main
findings in their study is that presynaptic dys-
function, including LTP deficits, precede the
accumulation of extracellular A[3 deposits, which,
in tum, precede tau alterations, the latter sequence
of events being in line with the amyloid cascade
hypothesis. Moreover, the results of this study
suggest an important role for intracellular A[3, in
the absence of structural changes, in cognitive
decline in AD. Recently, 3xTg mice have also been
studied for their cognitive behavior at different
time points (Billings et al., 2005). The earliest
cognitive impairment manifests at 4 months as a
deficit in long-term retention and correlates with
the accumulation of intraneuronal A[3 in the
hippocampus and amygdala. No plaques or tangles
are apparent at this age, suggesting that they
contribute to cognitive dysfunction at later time
points. Clearance of the intraneuronal A[3 pathology
by immunotherapy rescues the early cognitive
deficits on a hippocampal-dependent task, whereas
reemergence of the A[3 pathology again leads to
cognitive deficits. Triple-transgenic mice are now
being investigated at various, different levels and
are likely to provide more insight on the exact
sequence of pathological events leading to
Alzheimer (LaFerla& Oddo, 2005).
CONCLUSIONS
The use of genetic mouse models has certainly
been effective in research on the pathogenesis of
AD and has led to important insights into the
underlying pathological processes. In comparison
to 10 years ago, genetic mouse models have
evolved both in a qualitative and in a quantitative
way and seem to mimic AD neuropathology better
than the first genetically altered models. For
instance, the generation of the 3xTg-AD mice is a
step forward in animal modeling because such
transgenics develop both plaques and tangles in
the same order as AD patients do. The 3xTg-AD
model strongly implicates intraneuronal AI3 in the
onset of cognitive dysfunction, which might
facilitate therapeutic evaluations.
Another interesting line of research is the
inclusion of environmental factors in a genetic
design, which allows for the detection of gene-
environment interactions. In this respect, recent
studies by Lazarov et al. (2005) and Jankowski et308 Y.S. MINEUR ET AL.
al. (2003) are worth mentioning. Both groups
subjected double transgenics co-expressing APPswe
and PSI polypeptide variants, to an enriched
environment for longer periods and examined the
brains afterward. Although the results were not in
agreement for various reasons (see Lazarov et al.
(2005) for discussion), clearly environmental factors
can affect amyloid deposition in a genetic-
dependent way. The identification of such factors
would certainly be valuable in the treatment (or
prevention) ofAlzhe imer’s disease.
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